{"task_id": "94db8c5631ec5dad", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 135/464)", "text": " Cryp\ntosporidium (1.4/100,000)\n122\nAcute Diarrhea\n\n--- Page 144 ---\nPATHOPHYSIOLOGY (CONT\u2019D)\n\u0002\nTRAVELER\u2019S\nETEC\n\u0002\nNOSOCOMIAL\nC. difficile\n\u0002\nPERSISTENT DIARRHEA (>7 days)\nGiardia, Isospora\nbelli, Cyclospora, Cryptosporidium\n\u0002\nIMMUNOCOMPROMISED\nMicrosporidia, MAC, CMV\nNATURAL HISTORY\nmost diarrheal illnesses are\nself limited or viral induced and nearly 50% last\n<1 day\nCLINICAL FEATURES\nHISTORY\ncharacterize\ndiarrhea\n(duration,\nfre\nquency, volume, blood, floating), infectious contact,\nrecent food intake, abdominal pain, past medical\nhistory (IBD, lactose intolerance), medication history\n(laxatives, antibiotics), travel history\nPHYSICAL\nvitals\nand\ncheck\nfor\ndehydration.\nAbdominal tenderness. Perform a rectal examination\nand test for fecal occult blood. Inspect stool sample if\navailable\nSALMONELLA AND CAMPYLOBACTER\nalthough\nthey are classified as inflammatory, patients usually\nonly develop fever and severe diarrhea and not\nbloody diarrhea\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, lactate\n\u0002\nMICROBIOLOGY\nstool C&S (sens 1.5 5.6%), O&P,\nC. diff toxin A+B, viral culture\nSPECIAL\n\u0002\nFECAL TESTING\nfecal leukocytes (inflammatory,\nsens 73%, spc 84%), fecal lactoferrin (inflamma\ntory, sens 92%, spc 79%), Giardia toxin, fecal\noccult blood\n\u0002\nENDOSCOPY\nflexible sigmoidoscopy, colonoscopy\nMANAGEMENT\nSYMPTOM CONTROL\nIV hydration. Antidiar\nrheal agents if not inflammatory (bismuth subsalicy\nlate 2 tab PO q1h PRN or loperamide 4 mg \u00041 dose,\nthen 2 mg PO PRN, maximum 16 mg/day)\nTREAT UNDERLYING CAUSE\nShigella, Salmonella,\nCampylobacter, E. coli other than EHEC (ciprofloxacin\n500 mg PO BID \u0004 3 days, levofloxacin 500 mg PO daily\n\u00043 days). Vibrio cholera (tetracycline). Isospora and\nCyclospora (trimethoprim sulfamethoxazole 160/800\nPO BID \u00047 10 days). C. difficile, Giardia, and Enta\nmoeba (metronidazole 500 mg TID \u000410 days)\nRelated Topic\nAcute Abdominal Pain (p. 115)\nSPECIFIC ENTITIES\nANTIBIOTICS ASSOCIATED DIARRHEA AND\nPSEUDOMEMBRANOUS COLITIS\n\u0002\nPATHOPHYSIOLOGY\norganisms include C. difficile\n(particularly with clindamycin, cephalosporins,\npenicillins) and non C. difficile organisms (Salmo\nnella, C. perfringens, S. aureus, Candida). Relapse\noccurs in 20 25% of patients and typically\nbetween 3 and 21 days after discontinuation of\ntreatment: 3 5% of patients have more than 6\nrelapses. Note emergence of virulent C. difficile\nstrain NAP 1/027 characterized by increased secre\ntion of toxins A/B, binary toxin production and\nfluoroquinolone resistance, and associated with\nincreased outbreaks and mortality\n\u0002\nRISK FACTORS\nonset of diarrhea \u00056 days after the\ninitiation of antibiotic therapy, hospital stay \u00052\nweeks,\nfecal\nleukocytes,\nsemi formed\nstools,\ncephalosporin use\n\u0002\nCLINICAL FEATURES\nusually watery diarrhea (may\nbe bloody if severe colitis), abdominal pain. In\npatients with severe C. difficile infection, significant\nleukocytosis, pseudomembranous colitis, toxic\nmegacolon (see p. 120), acute renal failure, and\nhypotension may develop\n\u0002\nDIAGNOSIS\nC. difficile toxin A/B, colonoscopy\n(pseudomembranous colitis). C. difficile toxin levels\nare usually unnecessary immediately after treat\nment completion as up to one third of patients\nhave positive assays despite successful treatment\n\u0002\nTREATMENTS\nIV hydration. Discontinue impli\ncated antibiotics. Avoid use of antiperistaltic\nagents (opiates, loperamide). C. difficile treat\nment (metronidazole 250 mg PO QID \u000410 14\ndays or vancomycin 125 500 mg PO QID \u000410 14\ndays). For severe cases, consider oral vancomycin\nas first line agent. If significant ileus or toxic mega\ncolon, give vancomycin via NG or enema and add\nmetronidazole 500 mg IV QID. Avoid repeating\nstool assays after treatment unless patient has\nmoderate or severe diarrhea. A positive C. difficile\ntoxin without significant symptoms should not\nprompt treatment. For C. difficile recurrence,\nconsider retreatment with 14 day course and mini\nmize use of other antibiotics. For further recur\nrences, consider tapering doses of vancomycin\n125 mg PO QID \u00041 week, then BID \u00041 week,\nthen daily \u00041 week, then every other day \u00041\nweek, then every 3 days \u00042 weeks. Alternatives\ninclude vancomycin 125 mg PO QID and rifampin\n600 mg BID \u00047 days, or Saccharomyces boulardii\n250 mg PO QID in combination with metronida\nzole or vancomycin\nNEJM 2002 346:5; NEJM 2008 359:18\nAcute Diarrhea\n123", "text_length": 4314, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 135/464)", "type": "chunk", "chunk_index": 134, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.431499", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.432271", "status": "complete", "chunks_added": 3}